Article ; Online: Interchangeability and adverse events in originator-rituximab and its biosimilar (CT-P10) among rheumatic patients: a real-life experience.
Internal and emergency medicine
2023 Volume 18, Issue 3, Page(s) 791–799
Abstract: Biosimilars offer cost-effective and safe treatment options both for patients and healthcare systems. CT-P10 is the first biosimilar of rituximab approved in Europe for use in all indications of originator rituximab (oRTX). This study aimed to provide ... ...
Abstract | Biosimilars offer cost-effective and safe treatment options both for patients and healthcare systems. CT-P10 is the first biosimilar of rituximab approved in Europe for use in all indications of originator rituximab (oRTX). This study aimed to provide real-life data on treatment changes and adverse events in patients who received oRTX or CT-P10. We retrospectively reviewed treatment-related adverse events [infusion-related reactions (IRRs), infections, hypogammaglobulinemia] in patients treated with at least one dose of oRTX (MabThera |
---|---|
MeSH term(s) | Humans ; Rituximab/adverse effects ; Biosimilar Pharmaceuticals/adverse effects ; Agammaglobulinemia/chemically induced ; Agammaglobulinemia/drug therapy ; Retrospective Studies ; Treatment Outcome |
Chemical Substances | Rituximab (4F4X42SYQ6) ; CT-P10 ; Biosimilar Pharmaceuticals |
Language | English |
Publishing date | 2023-02-24 |
Publishing country | Italy |
Document type | Journal Article |
ZDB-ID | 2454173-4 |
ISSN | 1970-9366 ; 1828-0447 |
ISSN (online) | 1970-9366 |
ISSN | 1828-0447 |
DOI | 10.1007/s11739-023-03222-x |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 6673: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.